Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Screen Positive Women Living With HIV in C1001P-CS2 Kenya

Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its efficacy can be suboptimal in WLWH. In Kenya, the estimated incidence rate of cervical cancer is 31-33 per 100,000 women per year among women without HIV and approximately 70-100 per 100,000 among WLWH. The proposed study will evaluate t

Trial Details

NCT ID
NCT07468695
Phase
NA
Sponsor
Fred Hutchinson Cancer Center
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • Thermal ablation (TA) with 1 probe
  • Thermal ablation (TA) with 2 probes
Locations (sample)
  • Nairobi, Kenya|-1.28333,36.81667

Key Eligibility Criteria

  • 25-49 years old
  • Living with HIV
  • Inclusion criteria specific to the feasibility study
  • Intact cervix

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →